Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Efficacy of alemtuzumab i… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies

Artikel i vetenskaplig tidskrift
Författare G. Comi
R. Alroughani
A. L. Boster
A. D. Bass
R. Berkovich
O. Fernandez
H. J. Kim
V. Limmroth
Jan Lycke
R. A. L. Macdonell
B. Sharrack
B. A. Singer
P. Vermersch
H. Wiendl
T. Ziemssen
A. Jacobs
N. Daizadeh
C. E. Rodriguez
A. Traboulsee
Publicerad i Multiple Sclerosis Journal
Sidor 11
ISSN 1352-4585
Publiceringsår 2019
Publicerad vid Institutionen för neurovetenskap och fysiologi
Sidor 11
Språk en
Länkar dx.doi.org/10.1177/1352458519888610
Ämnesord Alemtuzumab, efficacy, multiple sclerosis, relapse, retreatment, safety, multiple-sclerosis, disease-activity, Neurosciences & Neurology
Ämneskategorier Neurologi

Sammanfattning

Background: Alemtuzumab is given as two annual courses. Patients with continued disease activity may receive as-needed additional courses. Objective: To evaluate efficacy and safety of additional alemtuzumab courses in the CARE-MS (Comparison of Alemtuzumab and Rebif (R) Efficacy in Multiple Sclerosis) studies and their extensions. Methods: Subgroups were based on the number of additional alemtuzumab courses received. Exclusion criteria: other disease-modifying therapy (DMT); Results: In the additional-courses groups, Courses 3 and 4 reduced annualized relapse rate (12 months before: 0.73 and 0.74, respectively; 12 months after: 0.07 and 0.08). For 36 months after Courses 3 and 4, 89% and 92% of patients were free of 6-month confirmed disability worsening, respectively, with 20% and 26% achieving 6-month confirmed disability improvement. Freedom from magnetic resonance imaging (MRI) disease activity increased after Courses 3 and 4 (12 months before: 43% and 53%, respectively; 12 months after: 73% and 74%). Safety was similar across groups; serious events occurred irrespective of the number of courses. Conclusion: Additional alemtuzumab courses significantly improved outcomes, without increased safety risks, in CARE-MS patients with continued disease activity after Course 2. How this compares to outcomes if treatment is switched to another DMT instead remains unknown.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?